AusperBio Therapeutics
AusperBio is a clinical-stage biotechnology company focused on advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB). They are developing AHB-137, a novel unconjugated antisense oligonucleotide, and are committed to delivering patient-centered innovations to alleviate the global health burden of CHB.
Funding Round: Series B+
Funding Amount: $50M
Date: 28-May-2025
Investors: Qiming Venture Partners, CDH Investments, Genesis Capital, YuanBio Venture Capital, HanKang Capital, Sherpa Capital
Markets: Biotech, Healthcare, Pharmaceuticals
HQ: San Francisco, California, United States
Founded: 2019
Website: https://www.ausperbio.com/
LinkedIn: https://www.linkedin.com/company/ausperbio
Crunchbase: https://www.crunchbase.com/organization/ausperbio
Leave a Comment
Comments
No comments yet.